Healthcare
Live Price
Offline$24.31
+0.79% today
1Y Change
+181.69%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 249 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Arcus Biosciences, Inc. (RCUS) is a Healthcare stock with a market cap of $2.59B and listed on NYSE. The stock last traded around $24.31 and up 181.7% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -4.3%, EPS growth of -4.8%, a dividend yield of 0.0%. What stands out right now is revenue -4.3%, EPS -4.8%, free cash flow -175.0% with operating margin -156.3% and ROIC -42.5%. Valuation already assumes a fairly strong business story at price/sales 10.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines RCUS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RCUS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RCUS Max Drawdown
-27.78%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RCUS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$383.0M
+242.0% YoY
FY Net Income
$53.0M
+119.9% YoY
Free Cash Flow
-$282.2M
-165.3% YoY
Revenue Growth
-4.3%
EPS Growth
-4.8%
Gross Margin
98.0%
Net Margin
-142.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 247M | 258M | 117M | 112M | 383M |
| Gross Profit | 237M | 258M | 117M | 112M | 383M |
| Operating Income | -386M | -330M | -340M | -280M | 54M |
| EBITDA | -335M | -269M | -291M | -258M | 59M |
| Net Income | -353M | -283M | -307M | -267M | 53M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 222M | 150M | 127M | 206M | 148M |
| Total Assets | 1.1B | 1.1B | 1.1B | 1.3B | 1.6B |
| Total Liabilities | 508M | 665M | 633M | 688M | 750M |
| Shareholder Equity | 631M | 485M | 462M | 657M | 841M |
| Total Debt | 99M | 60M | 11M | 120M | 122M |
| Net Debt | -123M | -90M | -116M | -86M | -26M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
256M
-158.5% YoY
Capital Expenditures
26M
-334.6% YoY
Free Cash Flow
282M
-165.3% YoY
Key ratios
Gross Margin
98.0%
Operating Margin
-156.3%
Net Margin
-142.9%
ROE
-65.8%
Debt / Equity
0.16x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.